Home » CEL-SCI Secures Manufacturing Facility for Cancer Drug
CEL-SCI Secures Manufacturing Facility for Cancer Drug
CEL-SCI entered into an agreement with a biomedical real estate group under which it acquires long-term use of a dedicated manufacturing plant near Baltimore for its cancer drug Multikine. The financial value of this transaction to CEL-SCI is about $15 million.
Genetic Engineering and biotechnology News
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May